Humanized anti-beta-amyloid antibodies
US8921523B2 · kind B2 · utility
4Cited by
1References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 9, 2008 |
| Grant date | Dec 30, 2014 |
| Priority date | — |
| Expiry date | Feb 11, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Antigen binding proteins that bind β-amyloid peptide, in particular human β-amyloid peptide; methods of treating diseases or disorders characterized by elevated β-amyloid levels or β-amyloid deposits, particularly Alzheimer's disease and diseases or disorders affecting the eye or optic nerve characterized by elevated β-amyloid levels or β-amyloid deposits, including age related macular degeneration and glaucoma type diseases and β-amyloid dependent cataract formation, with the antigen binding proteins; pharmaceutical compositions comprising the antigen binding proteins; and methods of manufacture.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.